CUTIA THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.62 HKD | +2.70% |
|
+12.56% | -30.60% |
| Apr. 30 | Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate | MT |
| Apr. 30 | Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6% | MT |
| Sales 2023 | 138M 19.01M 149M | Sales 2024 * | 282M 38.9M 304M | Capitalization | 2.09B 289M 2.26B |
|---|---|---|---|---|---|
| Net income 2023 | -1.96B -271M -2.12B | Net income 2024 * | -486M -67.12M -525M | EV / Sales 2023 | 22 x |
| Net cash position 2023 * | 315M 43.5M 340M | Net Debt 2024 * | 223M 30.8M 241M | EV / Sales 2024 * | 8.23 x |
| P/E ratio 2023 |
-1.04
x | P/E ratio 2024 * |
-4.3
x | Employees | 298 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 79.63% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.70% | ||
| 1 week | +12.56% | ||
| Current month | -3.42% | ||
| 1 month | +5.25% | ||
| 3 months | -6.85% | ||
| 6 months | -61.67% | ||
| Current year | -30.60% |
1 week
6.62
8.80
1 month
6.538.80
Current year
5.5711.00
1 year
5.5732.60
3 years
5.5732.60
5 years
5.5732.60
10 years
5.5732.60
| Managers | Title | Age | Since |
|---|---|---|---|
Le Le Zhang
FOU | Founder | 46 | 19-05-14 |
Yu Qing Huang
DFI | Director of Finance/CFO | 34 | 21-05-09 |
Lei Lei
CTO | Chief Tech/Sci/R&D Officer | 40 | 20-01-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tak Yan Tao
BRD | Director/Board Member | 48 | 23-05-31 |
Lian Yong Chen
CHM | Chairman | 62 | 19-08-22 |
Ming Kit Chung
BRD | Director/Board Member | 46 | 23-06-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 7.62 | +2.70% | 158 400 |
| 24-05-02 | 7.42 | +1.37% | 47,200 |
| 24-04-30 | 7.32 | -0.14% | 3,753,400 |
| 24-04-29 | 7.33 | +1.66% | 651,600 |
| 24-04-26 | 7.21 | +6.03% | 803,000 |
Delayed Quote Hong Kong S.E., May 03, 2024 at 04:09 am EDT
More quotes
Cutia Therapeutics is a China-based company mainly engaged in the research and development and manufacture of dermatological biological drugs. The Company is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The Company is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The Company conducts its businesses in the domestic market and overseas markets.
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.872
CNY
Average target price
16.85
CNY
Spread / Average Target
+145.24%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.60% | 289M | |
| +29.68% | 681B | |
| +19.48% | 556B | |
| -4.35% | 361B | |
| +17.65% | 325B | |
| +3.77% | 285B | |
| +13.47% | 235B | |
| +4.39% | 199B | |
| -12.39% | 189B | |
| -3.79% | 157B |
- Stock Market
- Equities
- 2487 Stock
